Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioacetamide SCHEMBL711294 | 1.00 | DPP4 (0.50) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL709483 | 0.89 | GRM8 (0.60) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL709482 | 0.89 | GRM8 (0.60) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL288407 | 0.77 | BLM (0.58) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL11478144 | 0.77 | BLM (0.58) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL29833669 | 0.77 | BLM (0.58) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL24140515 | 0.75 | GRM8 (0.58) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL85942 | 0.75 | GRM8 (0.58) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL8763003 | 0.75 | GRM8 (0.58) | DPP4DPP9DPP8GRM8GRM6 | |
| SCHEMBL4629339 | 0.73 | DPP4 (0.40) | DPP4DPP9DPP8GRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10792342-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190054154-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | GENZYME CORPORATION (US) | 2019-02-21 | — | — | US | disclosed |
| US-20170042979-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | GENZYME CORPORATION (US) | 2017-02-16 | — | — | US | disclosed |
| US-9498518-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150320844-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | GENZYME CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-8906379-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| EP-1877099-B1 | THERAPEUTIC CONJUGATES COMPRISING A LYSOSOMAL ENZYME, POLYSIALIC ACID AND A TARGETING MOIETY | GENZYME CORP (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20120141507-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | GENZYME CORPORATION | 2012-06-07 | — | — | US | disclosed |
| US-8124073-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2012-02-28 | — | — | US | disclosed |
| US-20080226658-A1 | Lysosomal conjugate for use in treatment of fabry, gaucher or niemann-pick diseases | GENZYME CORPORATION (US) | 2008-09-18 | — | — | US | disclosed |
| US-7341720-B2 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GENZYME CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1877099-A2 | PEG AND POLYSIALIC LYSOSOMAL ENZYME CONJUGATES VIA ACID LABILE LINKERS FOR THERAPEUTIC TARGETING | Genzyme Corporation (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20060228348-A1 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GENZYME CORPORATION | 2006-10-12 | — | — | US | disclosed |
| WO-2006108052-A2 | PEG AND POLYSIALIC LYSOSOMAL ENZYME CONJUGATES VIA ACID LABILE LINKERS FOR THERAPEUTIC TARGETING | GENZYME CORPORATION (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792342-B2 | Targeting of glycoprotein therapeutics | SIGLEC7, LAMP2, ASGR1 | DPP4 1574/4885DPP9 1593/4885DPP8 1596/4885 |
| US-20170042979-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | SIGLEC7, LAMP2, ASGR1 | DPP4 1574/4885DPP9 1593/4885DPP8 1596/4885 |
| US-20150320844-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | SIGLEC7, LAMP2, ASGR1 | DPP4 1574/4885DPP9 1593/4885DPP8 1596/4885 |
| US-20120141507-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | SIGLEC7, LAMP2, ASGR1 | DPP4 1574/4885DPP9 1593/4885DPP8 1596/4885 |
| US-20190054154-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | SIGLEC7, LAMP2, ASGR1 | DPP4 1574/4885DPP9 1593/4885DPP8 1596/4885 |
| US-20060228348-A1 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GAA, MAN2B1, GBA1 | DPP4 3050/4885DPP9 2706/4885DPP8 2794/4885 |
| US-20080226658-A1 | Lysosomal conjugate for use in treatment of fabry, gaucher or niemann-pick diseases | GAA, GBA1, MAN2B1 | DPP4 2029/4885DPP9 1692/4885DPP8 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.